Utility of reporting the percentage of high-grade prostate cancer

European Urology

Volumn 69, Issue 4, 2016, Pages 599-600

  Egevad, Lars ^a   Delahunt, Brett ^b   Samaratunga, Hemamali ^c   Srigley, John R ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Aquesta Pathology   (Australia)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELL; CANCER RECURRENCE; EDITORIAL; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; WORLD HEALTH ORGANIZATION; PROSTATE; PROSTATE TUMOR;

PROSTATE SPECIFIC ANTIGEN;

HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84959464775     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.11.008     Document Type: Editorial

References (12)

1. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. In press. http://dx.doi.org/10.1097/PAS.0000000000000530.
2. G. Sauter, S. Steurer, T. Clauditz, and et al. Clinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimens Eur Urol 69 2016 592 598
3. C. Morash, R. Tey, C. Agbassi, and et al. Active surveillance for the management of localized prostate cancer: guideline recommendations Can Urol Assoc J 9 2015 171 178
4. J.E. McNeal, A.A. Villers, E.A. Redwine, F.S. Freiha, and T.A. Stamey Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate Cancer 66 1990 1225 1233
5. T.A. Stamey, J.E. McNeal, C.M. Yemoto, B.M. Sigal, and I.M. Johnstone Biological determinants of cancer progression in men with prostate cancer JAMA 281 1999 1395 1400
6. L. Egevad, T. Granfors, L. Karlberg, A. Bergh, and P. Stattin Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection J Urol 168 2002 509 513
7. L. Egevad, K. Engström, S. Mattson, K. Wester, and C. Busch Heterogeneity of DNA ploidy in prostate cancer J Urol Pathol 10 1999 23 37
8. A. Glaessgen, H. Hamberg, C.G. Pihl, B. Sundelin, B. Nilsson, and L. Egevad Interobserver reproducibility of percent Gleason grade 4/5 in total prostatectomy specimens J Urol 168 2002 2006 2010
9. A. Glaessgen, H. Hamberg, C.G. Pihl, B. Sundelin, B. Nilsson, and L. Egevad Interobserver reproducibility of percent Gleason grade 4/5 in prostate biopsies J Urol 171 2004 664 667
10. D.M. Berney, F. Algaba, P. Camparo, and et al. The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists Histopathology 64 2014 405 411
11. J.A. Arias-Stella 3rd, A.B. Shah, D. Montoya-Cerrillo, S.R. Williamson, and N.S. Gupta Prostate biopsy and radical prostatectomy Gleason score correlation in heterogenous tumors: proposal for a composite Gleason score Am J Surg Pathol 39 2015 1213 1218
12. T.T. Tolonen, P.M. Kujala, T.L. Tammela, V.J. Tuominen, J.J. Isola, and T. Visakorpi Overall and worst Gleason scores are equally good predictors of prostate cancer progression BMC Urol 11 2011 21